MedTrace Logo

The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man

NCT02518932 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-08-10

No results posted yet for this study

Summary

To asses the modulating properties of the cleaved pentapeptide product of GLP-1 amide.

Conditions

Interventions

DRUG

Last 5 amino acids of GLP-1

To examine insulinomimetic properties of LVKGR

DRUG

placebo saline

Sponsors & Collaborators

  • ICON plc

    collaborator INDUSTRY

  • Massachusetts General Hospital

    collaborator OTHER

  • National Institute on Aging (NIA)

    collaborator NIH

  • Elahi, Dariush, PhD

    lead INDIV

Principal Investigators

  • Dariush Elahi, PhD · ICON plc, 8307 Gault Lane, San Antonio TX 78209

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02518932 on ClinicalTrials.gov